2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0420S2
    Succinic acid-13C4 201595-67-7 ≥98.0%
    Succinic acid-13C4 is the 13C labeled Succinic acid. Succinic acid is a potent and orally active anxiolytic agent. Succinic acid is an intermediate product of the tricarboxylic acid cycle. Succinic acid can be used as a precursor of many industrially important chemicals in food, chemical and pharmaceutical industries.
    Succinic acid-13C4
  • HY-N1378
    (E)-Cardamonin 19309-14-9 99.84%
    (E)-Cardamonin ((E)-Cardamomin) is a novel antagonist of hTRPA1 cation channel with an IC50 of 454 nM.
    (E)-Cardamonin
  • HY-100740
    Lanabecestat 1383982-64-6 99.87%
    Lanabecestat (AZD3293) is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM. Lanabecestat is used for the research of Alzheimer's disease.
    Lanabecestat
  • HY-100805
    D-Glutamic acid 6893-26-1 ≥99.0%
    D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods.
    D-Glutamic acid
  • HY-16642A
    LY2828360 1231220-79-3 99.50%
    LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.
    LY2828360
  • HY-13716
    Noscapine 128-62-1 99.98%
    Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier.
    Noscapine
  • HY-101186
    MK-6240 1841078-87-2 99.60%
    MK-6240 is a blood-brain barrier-permeable positron emission tomography (PET) tracer targeting neurofibrillary tangles (NFTs) (Kd = 0.42 nM). MK-6240 can be used for imaging neurofibrillary tangle pathology in Alzheimer's disease and hereditary frontotemporal dementia.
    MK-6240
  • HY-107670
    Dihydro-β-erythroidine hydrobromide 29734-68-7 ≥98.0%
    Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities.
    Dihydro-β-erythroidine hydrobromide
  • HY-137262
    Protein deglycase DJ-1 against-1 724737-74-0 99.86%
    Protein deglycase DJ-1 against-1, a DJ-1-binding compound, dependently targets DJ1. Protein deglycase DJ-1 against-1 penetrates through the blood brain barrier (BBB). Protein deglycase DJ-1 against-1 is used as a neuroprotective agent and has the potential for Parkinson's disease research.
    Protein deglycase DJ-1 against-1
  • HY-145778
    AGI-41998 2377492-26-5 99.94%
    AGI-41998 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that effectively penetrates the blood-brain barrier. AGI-41998 exhibits inhibitory activities against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC50s of 22 nM and 34 nM. AGI-41998 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-41998 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer.
    AGI-41998
  • HY-148794
    Risvodetinib 2031185-00-7 99.21%
    Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD.
    Risvodetinib
  • HY-P99164
    Zagotenemab 2019133-28-7 99.23%
    Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research.
    Zagotenemab
  • HY-P99185
    Bapineuzumab 648895-38-9
    Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).
    Bapineuzumab
  • HY-P9958A
    Denosumab (anti-TNFSF11) 615258-40-7
    Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.
    Denosumab (anti-TNFSF11)
  • HY-108703A
    Foliglurax monohydrochloride 2133294-96-7 98.57%
    Foliglurax monohydrochloride (PXT002331 monohydrochloride) is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) , with an EC50 of 79 nM. Antiparkinsonian effect.
    Foliglurax monohydrochloride
  • HY-120475A
    PBT434 mesylate 2387898-69-1 99.92%
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD).
    PBT434 mesylate
  • HY-W013136
    Triheptanoin 620-67-7
    Triheptanoin (Propane-1,2,3-triyl triheptanoate) is a synthetic medium-chain triglyceride (MCT) consisting of three odd-chain 7-carbon (heptanoate) fatty acids on a glycerol backbone. Triheptanoin can be used for the research of inherited metabolic disorders.
    Triheptanoin
  • HY-12206
    Thioperamide 106243-16-7 99.91%
    Thioperamide (MR-12842) is a potent, orally available, brain penetrant and selective H3 receptor antagonist with a Ki of 4.3 nM for inhibition of [3H]histamine release. Thioperamide inhibits [3H]histamine synthesis with a Ki of 31 nM.
    Thioperamide
  • HY-13457
    TCN 201 852918-02-6 99.06%
    TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC50 of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC50<4.3).
    TCN 201
  • HY-14399
    Itanapraced 749269-83-8 ≥98.0%
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease.
    Itanapraced
Cat. No. Product Name / Synonyms Application Reactivity